I
31.59
-1.03 (-3.16%)
| Previous Close | 32.62 |
| Open | 32.72 |
| Volume | 394,159 |
| Avg. Volume (3M) | 371,804 |
| Market Cap | 1,580,536,192 |
| Price / Sales | 5.48 |
| Price / Book | 4.32 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 |
| Profit Margin | -19.53% |
| Operating Margin (TTM) | -21.24% |
| Diluted EPS (TTM) | -1.10 |
| Quarterly Revenue Growth (YOY) | 26.20% |
| Total Debt/Equity (MRQ) | 131.69% |
| Current Ratio (MRQ) | 5.17 |
| Operating Cash Flow (TTM) | 11.24 M |
| Levered Free Cash Flow (TTM) | 23.05 M |
| Return on Assets (TTM) | -5.89% |
| Return on Equity (TTM) | -15.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immunocore Holdings plc | Bearish | Bearish |
Stockmoo Score
1.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.24% |
| % Held by Institutions | 95.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fiera Capital Corp | 30 Sep 2024 | 845,732 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (HC Wainwright & Co., 216.56%) | Buy |
| Median | 71.00 (124.76%) | |
| Low | 24.00 (UBS, -24.03%) | Sell |
| Average | 61.40 (94.37%) | |
| Total | 3 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 33.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 11 Nov 2024 | 38.00 (20.29%) | Hold | 34.64 |
| Needham | 07 Nov 2024 | 71.00 (124.75%) | Buy | 34.31 |
| 17 Sep 2024 | 78.00 (146.91%) | Buy | 33.90 | |
| HC Wainwright & Co. | 24 Oct 2024 | 100.00 (216.56%) | Buy | 32.50 |
| 17 Sep 2024 | 100.00 (216.56%) | Buy | 33.90 | |
| UBS | 24 Oct 2024 | 24.00 (-24.03%) | Sell | 32.50 |
| Morgan Stanley | 11 Oct 2024 | 74.00 (134.25%) | Buy | 31.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Nov 2024 | Announcement | Immunocore to present at upcoming investor conferences |
| 06 Nov 2024 | Announcement | Immunocore reports third quarter financial results and provides a business update |
| 14 Sep 2024 | Announcement | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer |
| 12 Sep 2024 | Announcement | Immunocore to present at the 2024 Cantor Global Healthcare Conference |
| 29 Aug 2024 | Announcement | Immunocore announces transition of Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |